Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Abstract withdrawn as it was not presented at the Meeting
P39 - Can advances in molecular methods improve the management and outcomes of Non-Tuberculous Mycobacterial Lung Disease (NTM-LD)? A service evaluation of laboratory and clinical management of NTM-LD in a large teaching hospital in England
Amendments to text in abstracts
P189 - Use of Angiotensin-Converting-Enzyme Inhibitors and Angiotensin Receptor Blockers in COVID-19 infection does not adversely affect clinical outcomes including need for Non-Invasive and Invasive Ventilation
It has been hypothesised that use of Angiotensin-Converting-Enzyme Inhibitors (ACE-I) and Angiotensin Receptor Blockers (ARB) are associated with worse outcomes in COVID-19 through upregulation of ACE2 receptors1. Recent studies have shown no association between ACE-I/ARB use and increased mortality but there is limited information on other markers of disease severity such as need for non-invasive and invasive ventilation. We assessed the effect of ACE-I/ARB on the outcomes of COVID-19 patients.
A retrospective observational cohort study of patients with confirmed COVID-19 admitted to the respiratory units during a 1 year period. Patient demographics, clinical and medication history and clinical outcomes were extracted from written and electronic records. Primary outcomes – length of stay (LOS), NIV requirement, intensive care (ITU) admission, intubation and death – were compared between those who received ACE-I/ARB concurrently with their COVID-19 treatment and those who did not. Statistical analysis was performed using chi-squared test and OR.
Of 521 patients with confirmed COVID-19 (median age 59 years, 62.6% male), 183 (35.1%) required NIV, 108 (20.7%) were admitted to ITU, 60 (11.5%) were intubated and 41 (7.9%) died. In total, 151 (29%) were on ACE-I/ARB treatment, most commonly for hypertension. There was no difference in median LOS between those on ACE-I/ARB treatment and those not (11 and 10 days respectively, p=0.20). There was no difference between NIV requirement (OR 1.13, 95% CI 0.71 to 1.56), admission to intensive care (OR 0.64, 95% CI 0.50 to 1.36), intubation (OR 0.65, 95% CI 0.43 to 1.58) and death (OR 1.15, 95% CI 0.53 to 2.11) between the two groups (p>0.05).
There was no difference in clinical outcomes between COVID-19 patients on ACE-I/ARB and those who were not, in particular with regards to need for non-invasive and invasive ventilation. Our findings support current recommendations for continued use of ACE-I/ARB in COVID-19 infection.
Amendment to author list
S25 - Cardiopulmonary exercise testing to evaluate exercise limitation and shortness of breath in long COVID-19
L Godinho, T Wallis, D Levett, S Jack, T Wilkinson, B Marshall, A Banerjee, A Freeman
University of Southampton, Southampton, UK
S80 - The diagnosis and management of catheter-associated upper-extremity deep venous thrombosis (CA-UEDVT): a systematic review
1O Aniftos, 2A Scott, 3A Kafai Golahmadi, 1A Chapman
1Ashford and St Peter’s Hospital Trust, Chertsey, UK;
2St George’s University of London, London, UK
3School of Medicine, Imperial College London, London, UK
Amendment to table
P7 - Remote Frailty Assessment and Prevalence of Frailty in Older Outpatients with Idiopathic Pulmonary Fibrosis